JUNS
Jupiter Neurosciences, Inc.
There isn't enough reported data to score JUNS yet.
LLY
Eli Lilly and Company
LLY's fundamentals are strong: revenue grew 46% and it turned 23% of its revenue into free cash flow. At 46x earnings, it's trading in line with its usual 48x. Analysts expect that strong growth to continue.
JUNS Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Weak | |
| Unavailable | |
| Unavailable |
JUNS's profitability is currently weak. There isn't enough data to rate its revenue, cash flow and balance sheet.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
JUNS PE Valuation
JUNS has no meaningful PE right now: it lost money over the past year.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
JUNS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| -- | |
| Limited | |
| High |
Analysts expect JUNS's losses to shrink, with revenue growing.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
JUNS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$18.33 | -$4.14 |
| Q1 2026 | -$19.50 | -$11.27 |
| Q4 2025 | -$18.75 | -$12.83 |
| Q3 2025 | -$17.94 | -$14.65 |
| Q2 2025 | -$14.19 | -$7.36 |
| Q1 2025 | -$8.23 | +$1.21 |
| Q4 2024 | -$5.92 | +$5.44 |
| Q2 2022 | -$38.70 | -$21.74 |
JUNS is still losing money, but far less than before: $18.33 per share over the past year, against $39.92 at its worst in early 2022.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over JUNS on earnings quality, reporting a profit while its opponent remains loss making.
JUNS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2022 | $233.3K | -12% |
JUNS's revenue is growing: $24,245 last quarter.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -11313% | N/A |
| Q1 2026 | -10524% | N/A |
| Q2 2022 | -297% | +31 points |
| Q2 2021 | -328% | N/A |
| Q1 2021 | -61% | N/A |
| Q4 2020 | -45% | N/A |
JUNS's operating margin was −11313% last quarter, down 11252 points from the same quarter a year ago, near the bottom of its range since 2020.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY's revenue has grown year over year for 14 quarters in a row: $24.4B last quarter, up 39% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over JUNS on profitability, with a higher operating margin.
JUNS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$2.3M | -$1.5M |
| Q1 2026 | -$1.4M | -$369.1K |
| Q4 2025 | -$2.4M | +$1.3M |
| Q2 2025 | -$828.2K | -$720.8K |
| Q1 2025 | -$1.1M | -$997.9K |
| Q4 2024 | -$3.7M | -$3.5M |
| Q2 2024 | -$107.5K | -$49.5K |
| Q1 2024 | -$65.2K | +$33.5K |
JUNS has burned cash in almost every quarter: −$7M over the past year, against −$6M the year before.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over JUNS on cash generation, producing positive trailing cash flow while its opponent burns cash.
JUNS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +19% | +87.5K shares |
| 1 year | +26% | +115K shares |
| 3 years | +27% | +119K shares |
| 5 years | +371% | +439K shares |
JUNS has 557,567 diluted shares, up 26% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2024 | — |
| Q1 2024 | — |
| Q4 2023 | — |
| Q3 2023 | — |
| Q2 2023 | — |
| Q1 2023 | — |
| Q2 2022 | — |
| Q1 2022 | — |
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over JUNS on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
JUNS Net Leverage
JUNS's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
JUNS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 32.2 | Neutral |
| Stochastic | 0.9 | Oversold |
JUNS's weekly RSI is 32 (neutral) and its Stochastic is 1 (oversold).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
JUNS PE vs Healthcare Sector
JUNS has no meaningful PE right now: it lost money over the past year.
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
JUNS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $2.51 | 26% below |
| 20 week MA | $5.49 | 66% below |
| 50 week MA | $27.4 | 93% below |
| 100 week MA | $83.4 | 98% below |
LLY has stronger trend alignment. JUNS is above 0 of 4 weekly averages versus LLY above 5 of 5.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY is in an uptrend: it's above all five of its weekly moving averages, and 79% above its 200-week average.
JUNS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2024 | $584.3 | $826.5 | +41% |
| 2025 | $826.5 | $85.5 | -90% |
| 2026 YTD | $85.5 | $1.86 | -98% |
JUNS has finished lower in one of the last two years. It's down 98% so far in 2026.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over JUNS on returns for 2026, with the stronger performance.